HALO
What one share of Halozyme Therapeutics holds
Biological Products, (No Diagnostic Substances)
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
Halozyme Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $13.61 |
|---|---|
| Profit | $3.38 |
| Capex (buildings and equipment) | $0.10 |
| Free cash flow | $6.60 |
| Cash and investments | $1.43 |
| Debt | $18.82 |
| Book value | $1.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.15 | −$0.81 | $0.02 | −$0.42 | — | −$0.25 |
| 2017 | $2.28 | $0.45 | $0.01 | $0.95 | — | $1.46 |
| 2018 | $1.06 | −$0.56 | $0.03 | −$0.38 | — | $1.72 |
| 2019 | $1.36 | −$0.50 | $0.03 | −$0.62 | — | $0.67 |
| 2020 | $1.89 | $0.91 | $0.02 | $0.37 | — | $1.12 |
| 2021 | $3.02 | $2.74 | $0.01 | $2.03 | — | $1.43 |
| 2022 | $4.69 | $1.44 | $0.03 | $1.67 | — | $1.26 |
| 2023 | $6.18 | $2.10 | $0.11 | $2.78 | — | $0.66 |
| 2024 | $7.84 | $3.43 | $0.08 | $3.62 | — | $2.95 |
| 2025 | $11.27 | $2.56 | $0.06 | $5.20 | — | $0.41 |